EndometriosisNCT03136978
Evaluation of M1 and M2 Macrophages in Endometriotic Tissue of Women Affected by Endometriosis at Different Stages.
An observational study of Endometriosis, run by University of Messina at 1 site in Italy.
Trial summary
Accumulating evidence suggests that the peritoneal microenvironment of women affected by endometriosis undergoes a number of local inflammatory-reparative phenomena, with the involvement of resident macrophages, and the attraction and recruitment of peripheral mononuclear cells (monocytes and lymphocytes) from the… Read more about this study
- Who is it for?
- Ages 18 to 35 years, women only
- Conditions the study is for
- Endometriosis
- What is being tested?
- Evaluation of M1 and M2 macrophages by flow cytometry.
- How many people
- 45 participants
- Where
- 1 siteItaly
- Study dates
- Dec 2016to Dec 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- No healthy volunteers
- Adult
Study population: Reproductive-aged patients affected by histologically confirmed endometriosis (cases) and by ovarian functional cysts (controls), who will undergo laparoscopic surgery.
Who may be able to join
- Patients affected by histologically confirmed endometriosis (cases)
- Patients affected by ovarian function cysts (controls)
Who cannot join
- Other pelvic disorders (apart ovarian functional cysts)
- Chronic circulatory disorders
- Autoimmune disorders
- Neoplastic disorders
- Patients who were treated with any anti-inflammatory or hormonal or immunomodulatory medication in the preceding 6 months.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Evaluate M1 and M2 Macrophages in Endometriotic Tissue of Women Affected by Endometriosis at Different Stages.
Accumulating evidence suggests that the peritoneal microenvironment of women affected by endometriosis undergoes a number of local inflammatory-reparative phenomena, with the involvement of resident macrophages, and the attraction and recruitment of peripheral mononuclear cells (monocytes and lymphocytes) from the blood into the peritoneal cavity: during endometriosis a breakdown occurs in endometrial and peritoneal homeostasis caused by cytokine-addressed cell proliferation and dysregulation of apoptosis.
The surrounding microenvironment may address the macrophage plasticity towards a transient and reversible polarization. These polarized phenotypes reflects the proinflammatory or anti-inflammatory status and may change over the time. They could be functionally classified in two main populations: "classically activated" macrophages (M1) and "alternatively activated" macrophages (M2).
Considering that published data so far are still not robust enough to drawn firm conclusion, the aim of this research project will be to evaluate M1 and M2 macrophages in endometriotic tissue from women affected by endometriosis at different stages.
Read the detailed description
Background and rationale: Endometriosis is an estrogen-dependent disease defined by the ectopic presence and growth of functional endometrial tissue, glands and stroma, outside the uterine cavity (Kavoussi et al, 2016). The aetiopathogenesis of endometriosis still remains controversial: immune, hormonal, genetic, and epigenetic factors may be all involved, and several theories have been proposed to explain it.
The disease affects 2-10 % of women of reproductive age and 50 % of those infertile (Dunselman et al, 2014) and may cause pelvic pain (Triolo et al, 2013; Butticè et al, 2013), abnormal bleeding, infertility/sterility and, consequently, important psychological problems (Laganà et al, 2015). Endometriosis is classified depending on the number, size, and superficial and/or deep location of endometrial implants, plaques, endometriomas and/or adhesions. The most used classification of endometriosis was developed by the American Society for Reproductive Medicine (Rock JA, 1995), although other classification can be used for deep infiltrating endometriosis (Haas et al, 2011) or to correlate endometriosis and infertility (Adamson et al, 2010).
As widely evidenced (Donnez et al, 2016), it is generally accepted that moderate/severe endometriosis-related sterility is due to mechanical factors, namely to the distortion/subversion of the regular pelvic anatomy. On the contrary, the factors behind infertility/subfertility related to minimal/mild endometriosis are less clear. Nevertheless, to date none of the hypothesized mechanisms exhaustively explained the infertility related to endometriosis, while it is possible that such disease is caused by multiple factors altogether, including genetic and epigenetic modifications (Sofo et al, 2015; Maniglio et al, 2016).
Accumulating evidence (Laganà et al, 2013; Laganà et al, 2016) suggests that the peritoneal microenvironment of women affected by endometriosis undergoes a number of local inflammatory-reparative phenomena, with the involvement of resident macrophages, and the attraction and recruitment of peripheral mononuclear cells (monocytes and lymphocytes) from the blood into the peritoneal cavity: during endometriosis a breakdown occurs in endometrial and peritoneal homeostasis caused by cytokine-addressed cell proliferation (Pizzo et al, 2002) and dysregulation of apoptosis (Sturlese et al, 2011; Salmeri et al, 2015).
Monocytes play a key role during adaptive immunity, since they migrates in sites of infection or inflammation, differentiate in macrophages and act as Antigene Presenting Cells (APCs).
Since their first identification of phagocytosis by Elie Metchnikoff in Messina (JAMA, 1968), after experimenting on the larvae of starfish, many steps forward allowed us to have a wide overview of macrophages apart from their role as phagocytic cells.
The surrounding microenvironment may address the macrophage plasticity towards a transient and reversible polarization. These polarized phenotypes reflects the proinflammatory or anti-inflammatory status and may change over the time. They could be functionally classified in two main populations: "classically activated" macrophages (M1) and "alternatively activated" macrophages (M2) (Sica \& Mantovani, 2012). Although it is widely accepted that M1 and M2 represent two terminals of the full spectrum of macrophage activation (Liu et al, 2014), recent data (Locati et al, 2013; Mantovani et al, 2013; Capobianco \& Rovere-Querini, 2013) allowed to characterize these two populations as follow:
- M1 Macrophages: CD14+ CD68+ CCR7+ CD80+
- M2 Macrophages: CD14+ CD68+ CD163+ CD206+
Study Population: The investigators will select patients affected by histologically confirmed endometriosis (cases) and by ovarian functional cysts (controls), who will undergo laparoscopic surgery. In accordance with the revised American Society for Reproductive Medicine classification for endometriosis (Rock JA, 1995), endometriotic patients will be divided into 4 groups: minimal, mild, moderate and severe stages of endometriosis.
All the laparoscopic procedure will be performed during the proliferative phase of the menstrual cycle. The investigators will exclude from the study women affected by other pelvic disorders, chronic circulatory, autoimmune or neoplastic disease and who took any anti-inflammatory or hormonal or immunomodulatory medication in the preceding 6 months.
Tissue sample preparation and macrophage characterization: Tissue sections (endometriotic tissues for cases, ovarian functional cysts for controls) will be minced and incubated in an enzyme cocktail containing final concentrations of 3.4 mg/ml pancreatin, 0.1 mg/ml hyaluronidase and 1.6 mg/ml collagenase I in Hank's Buffered Saline Solution (HBSS) containing 2 mg/ml D-glucose at 37°C for 2 hours. Following digestion, cells will be dispersed by straining through a 250 μm mesh screen and washed with HBSS. Tissue cells will be stained and fixed for flow cytometric analysis. Prior to macrophage isolation, dead cells will be removed from the culture using the dead cell removal kit. Cell viability will be assessed by trypan blue exclusion.
To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
Statistical analysis: The assumption of normal distribution for continuous variables will be tested by Kolmogorov-Smirnov test for goodness of fit. All inferential analyses will be performed using nonparametric statistical tests. Non-normally distributed variables between the groups will be compared using the Kruskal-Wallis test. The range of statistical significance will be P < .05. In addition, The investigators will use post hoc multiple comparison tests either versus controls or versus each stage to analyze data.
- Conditions
- Endometriosis
- Being tested
- Evaluation of M1 and M2 macrophages by flow cytometry.
- Keywords
- Macrophages, Macrophages, Peritoneal, Endometriosis
- Medical subject headings
- Endometriosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Evaluation of M1 and M2 macrophages by flow cytometry.Diagnostic test
To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
| Study group | Role | What they receive |
|---|---|---|
| Endometriosis | Patients affected by endometriosis (histologically confirmed) at different stages, who will undergo laparoscopic surgery. Receives: Diagnostic Test: Evaluation of M1 and M2 macrophages by flow cytometry. | |
| Ovarian functional cysts | Patients affected by ovarian functional cysts, who will undergo laparoscopic surgery. Receives: Diagnostic Test: Evaluation of M1 and M2 macrophages by flow cytometry. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quantification of M1 and M2 macrophages in endometriotic tissue for each stage of endometriosis.
To assess surface expression of macrophage markers, endometrial tissue cells will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
Measured: Day 1
Secondary outcomes (2)
Correlation of M1 and M2 macrophages quantity in endometriotic tissue to the presence of endometriosis-associated infertility.
To assess surface expression of macrophage markers, endometrial tissue cells will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2. Female infertility will be defined by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse.
Measured: Day 1
Correlation of M1 and M2 macrophages quantity in endometriotic tissue to the presence of endometriosis-associated chronic pelvic pain.
To assess surface expression of macrophage markers, endometrial tissue cells will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2. Chronic pelvic pain will be defined as pain that occurs below the umbilicus (belly button) that lasts for at least six months.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 May 2017
- Study startDec 2016
- Primary completionDec 2018
- Study completionDec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (22)Papers the sponsor has linked to this study.
- Other trials for EndometriosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 45 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Messina
- Sponsor type
- University, hospital or other
- Collaborators
- University of Ljubljana, University of Padova
- Responsible party
- Principal investigator, Antonio Simone Laganà, University of Messina
- Investigators
- Antonio Simone Laganà, M.D., Principal investigator, University of Messina
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03136978
- Sponsor's protocol ID
- ENDOMAC
- Status last verified
- Mar 2020
- First submitted
- 27 Apr 2017
- Last updated
- 24 Mar 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Kavoussi SK, Lim CS, Skinner BD, Lebovic DI, As-Sanie S. New paradigms in the diagnosis and management of endometriosis. Curr Opin Obstet Gynecol. 2016 Aug;28(4):267-76. doi: 10.1097/GCO.0000000000000288.
PubMed 27306924Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014 Mar;29(3):400-12. doi: 10.1093/humrep/det457. Epub 2014 Jan 15.
PubMed 24435778Triolo O, Lagana AS, Sturlese E. Chronic pelvic pain in endometriosis: an overview. J Clin Med Res. 2013 Jun;5(3):153-63. doi: 10.4021/jocmr1288w. Epub 2013 Apr 23.
PubMed 23671540Buttice S, Lagana AS, Barresi V, Inferrera A, Mucciardi G, Di Benedetto A, D'Amico CE, Magno C. Lumbar Ureteral Stenosis due to Endometriosis: Our Experience and Review of the Literature. Case Rep Urol. 2013;2013:812475. doi: 10.1155/2013/812475. Epub 2013 May 2.
PubMed 23738189Lagana AS, Condemi I, Retto G, Muscatello MR, Bruno A, Zoccali RA, Triolo O, Cedro C. Analysis of psychopathological comorbidity behind the common symptoms and signs of endometriosis. Eur J Obstet Gynecol Reprod Biol. 2015 Nov;194:30-3. doi: 10.1016/j.ejogrb.2015.08.015. Epub 2015 Aug 15.
PubMed 26319653Rock JA. The revised American Fertility Society classification of endometriosis: reproducibility of scoring. ZOLADEX Endometriosis Study Group. Fertil Steril. 1995 May;63(5):1108-10. doi: 10.1016/s0015-0282(16)57556-6.
PubMed 7720925Haas D, Chvatal R, Habelsberger A, Wurm P, Schimetta W, Oppelt P. Comparison of revised American Fertility Society and ENZIAN staging: a critical evaluation of classifications of endometriosis on the basis of our patient population. Fertil Steril. 2011 Apr;95(5):1574-8. doi: 10.1016/j.fertnstert.2011.01.135.
PubMed 21315335Adamson GD, Pasta DJ. Endometriosis fertility index: the new, validated endometriosis staging system. Fertil Steril. 2010 Oct;94(5):1609-15. doi: 10.1016/j.fertnstert.2009.09.035.
PubMed 19931076Donnez J, Donnez O, Orellana R, Binda MM, Dolmans MM. Endometriosis and infertility. Panminerva Med. 2016 Jun;58(2):143-50. Epub 2016 Feb 2.
PubMed 26837776Sofo V, Gotte M, Lagana AS, Salmeri FM, Triolo O, Sturlese E, Retto G, Alfa M, Granese R, Abrao MS. Correlation between dioxin and endometriosis: an epigenetic route to unravel the pathogenesis of the disease. Arch Gynecol Obstet. 2015 Nov;292(5):973-86. doi: 10.1007/s00404-015-3739-5. Epub 2015 Apr 29.
PubMed 25920525Maniglio P, Ricciardi E, Lagana AS, Triolo O, Caserta D. Epigenetic modifications of primordial reproductive tract: A common etiologic pathway for Mayer-Rokitansky-Kuster-Hauser Syndrome and endometriosis? Med Hypotheses. 2016 May;90:4-5. doi: 10.1016/j.mehy.2016.02.015. Epub 2016 Feb 27. No abstract available.
PubMed 27063075Lagana AS, Sturlese E, Retto G, Sofo V, Triolo O. Interplay between Misplaced Mullerian-Derived Stem Cells and Peritoneal Immune Dysregulation in the Pathogenesis of Endometriosis. Obstet Gynecol Int. 2013;2013:527041. doi: 10.1155/2013/527041. Epub 2013 Jun 13.
PubMed 23843796Lagana AS, Triolo O, Salmeri FM, Granese R, Palmara VI, Ban Frangez H, Vrtcnik Bokal E, Sofo V. Natural Killer T cell subsets in eutopic and ectopic endometrium: a fresh look to a busy corner. Arch Gynecol Obstet. 2016 May;293(5):941-9. doi: 10.1007/s00404-015-4004-7. Epub 2016 Jan 6.
PubMed 26739265Pizzo A, Salmeri FM, Ardita FV, Sofo V, Tripepi M, Marsico S. Behaviour of cytokine levels in serum and peritoneal fluid of women with endometriosis. Gynecol Obstet Invest. 2002;54(2):82-7. doi: 10.1159/000067717.
PubMed 12566749Sturlese E, Salmeri FM, Retto G, Pizzo A, De Dominici R, Ardita FV, Borrielli I, Licata N, Lagana AS, Sofo V. Dysregulation of the Fas/FasL system in mononuclear cells recovered from peritoneal fluid of women with endometriosis. J Reprod Immunol. 2011 Dec;92(1-2):74-81. doi: 10.1016/j.jri.2011.08.005. Epub 2011 Oct 5.
PubMed 21978769
Study at a glance
From the registry record, last updated by the sponsor on 24 Mar 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Evaluate M1 and M2 Macrophages in Endometriotic Tissue of Women Affected by Endometriosis at Different Stages.
- ClinicalTrials.gov ID
- NCT03136978
- Acronym / sponsor ID
- ENDOMAC
- Conditions
- Endometriosis
- Keywords
- Macrophages, Macrophages, Peritoneal, Endometriosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 45 participants (actual)
- Lead sponsor
- University of MessinaUniversity, hospital or other
- Collaborators
- University of Ljubljana, University of Padova
- Study start
- Dec 2016 (actual)
- Primary completion
- Dec 2018 (actual)
- Study completion
- Dec 2019 (actual)
- First posted
- 2 May 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Accumulating evidence suggests that the peritoneal microenvironment of women affected by endometriosis undergoes a number of local inflammatory-reparative phenomena, with the involvement of resident macrophages, and the attraction and recruitment of peripheral mononuclear cells (monocytes and lymphocytes) from the blood into the peritoneal cavity: during endometriosis a breakdown occurs in endometrial and peritoneal homeostasis caused by cytokine-addressed cell proliferation and dysregulation of apoptosis.
The surrounding microenvironment may address the macrophage plasticity towards a transient and reversible polarization. These polarized phenotypes reflects the proinflammatory or anti-inflammatory status and may change over the time. They could be functionally classified in two main populations: "classically activated" macrophages (M1) and "alternatively activated" macrophages (M2).
Considering that published data so far are still not robust enough to drawn firm conclusion, the aim of this research project will be to evaluate M1 and M2 macrophages in endometriotic tissue from women affected by endometriosis at different stages.
Detailed description
Background and rationale: Endometriosis is an estrogen-dependent disease defined by the ectopic presence and growth of functional endometrial tissue, glands and stroma, outside the uterine cavity (Kavoussi et al, 2016). The aetiopathogenesis of endometriosis still remains controversial: immune, hormonal, genetic, and epigenetic factors may be all involved, and several theories have been proposed to explain it.
The disease affects 2-10 % of women of reproductive age and 50 % of those infertile (Dunselman et al, 2014) and may cause pelvic pain (Triolo et al, 2013; Butticè et al, 2013), abnormal bleeding, infertility/sterility and, consequently, important psychological problems (Laganà et al, 2015). Endometriosis is classified depending on the number, size, and superficial and/or deep location of endometrial implants, plaques, endometriomas and/or adhesions. The most used classification of endometriosis was developed by the American Society for Reproductive Medicine (Rock JA, 1995), although other classification can be used for deep infiltrating endometriosis (Haas et al, 2011) or to correlate endometriosis and infertility (Adamson et al, 2010).
As widely evidenced (Donnez et al, 2016), it is generally accepted that moderate/severe endometriosis-related sterility is due to mechanical factors, namely to the distortion/subversion of the regular pelvic anatomy. On the contrary, the factors behind infertility/subfertility related to minimal/mild endometriosis are less clear. Nevertheless, to date none of the hypothesized mechanisms exhaustively explained the infertility related to endometriosis, while it is possible that such disease is caused by multiple factors altogether, including genetic and epigenetic modifications (Sofo et al, 2015; Maniglio et al, 2016).
Accumulating evidence (Laganà et al, 2013; Laganà et al, 2016) suggests that the peritoneal microenvironment of women affected by endometriosis undergoes a number of local inflammatory-reparative phenomena, with the involvement of resident macrophages, and the attraction and recruitment of peripheral mononuclear cells (monocytes and lymphocytes) from the blood into the peritoneal cavity: during endometriosis a breakdown occurs in endometrial and peritoneal homeostasis caused by cytokine-addressed cell proliferation (Pizzo et al, 2002) and dysregulation of apoptosis (Sturlese et al, 2011; Salmeri et al, 2015).
Monocytes play a key role during adaptive immunity, since they migrates in sites of infection or inflammation, differentiate in macrophages and act as Antigene Presenting Cells (APCs).
Since their first identification of phagocytosis by Elie Metchnikoff in Messina (JAMA, 1968), after experimenting on the larvae of starfish, many steps forward allowed us to have a wide overview of macrophages apart from their role as phagocytic cells.
The surrounding microenvironment may address the macrophage plasticity towards a transient and reversible polarization. These polarized phenotypes reflects the proinflammatory or anti-inflammatory status and may change over the time. They could be functionally classified in two main populations: "classically activated" macrophages (M1) and "alternatively activated" macrophages (M2) (Sica \& Mantovani, 2012). Although it is widely accepted that M1 and M2 represent two terminals of the full spectrum of macrophage activation (Liu et al, 2014), recent data (Locati et al, 2013; Mantovani et al, 2013; Capobianco \& Rovere-Querini, 2013) allowed to characterize these two populations as follow:
- M1 Macrophages: CD14+ CD68+ CCR7+ CD80+
- M2 Macrophages: CD14+ CD68+ CD163+ CD206+
Study Population: The investigators will select patients affected by histologically confirmed endometriosis (cases) and by ovarian functional cysts (controls), who will undergo laparoscopic surgery. In accordance with the revised American Society for Reproductive Medicine classification for endometriosis (Rock JA, 1995), endometriotic patients will be divided into 4 groups: minimal, mild, moderate and severe stages of endometriosis.
All the laparoscopic procedure will be performed during the proliferative phase of the menstrual cycle. The investigators will exclude from the study women affected by other pelvic disorders, chronic circulatory, autoimmune or neoplastic disease and who took any anti-inflammatory or hormonal or immunomodulatory medication in the preceding 6 months.
Tissue sample preparation and macrophage characterization: Tissue sections (endometriotic tissues for cases, ovarian functional cysts for controls) will be minced and incubated in an enzyme cocktail containing final concentrations of 3.4 mg/ml pancreatin, 0.1 mg/ml hyaluronidase and 1.6 mg/ml collagenase I in Hank's Buffered Saline Solution (HBSS) containing 2 mg/ml D-glucose at 37°C for 2 hours. Following digestion, cells will be dispersed by straining through a 250 μm mesh screen and washed with HBSS. Tissue cells will be stained and fixed for flow cytometric analysis. Prior to macrophage isolation, dead cells will be removed from the culture using the dead cell removal kit. Cell viability will be assessed by trypan blue exclusion.
To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
Statistical analysis: The assumption of normal distribution for continuous variables will be tested by Kolmogorov-Smirnov test for goodness of fit. All inferential analyses will be performed using nonparametric statistical tests. Non-normally distributed variables between the groups will be compared using the Kruskal-Wallis test. The range of statistical significance will be P < .05. In addition, The investigators will use post hoc multiple comparison tests either versus controls or versus each stage to analyze data.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Endometriosis | – | Diagnostic Test: Evaluation of M1 and M2 macrophages by flow cytometry.Patients affected by endometriosis (histologically confirmed) at different stages, who will undergo laparoscopic surgery. |
| Ovarian functional cysts | – | Diagnostic Test: Evaluation of M1 and M2 macrophages by flow cytometry.Patients affected by ovarian functional cysts, who will undergo laparoscopic surgery. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Reproductive-aged patients affected by histologically confirmed endometriosis (cases) and by ovarian functional cysts (controls), who will undergo laparoscopic surgery.
Key inclusion criteria (2 listed)
- Patients affected by histologically confirmed endometriosis (cases)
- Patients affected by ovarian function cysts (controls)
Key exclusion criteria (5 listed)
- Other pelvic disorders (apart ovarian functional cysts)
- Chronic circulatory disorders
- Autoimmune disorders
- Neoplastic disorders
- Patients who were treated with any anti-inflammatory or hormonal or immunomodulatory medication in the preceding 6 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Evaluation of M1 and M2 macrophages by flow cytometry.To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2. | Diagnostic test | Endometriosis, Ovarian functional cysts |
Primary outcome
Quantification of M1 and M2 macrophages in endometriotic tissue for each stage of endometriosis.
Time frame: Day 1
To assess surface expression of macrophage markers, endometrial tissue cells will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
2 secondary outcomes
Correlation of M1 and M2 macrophages quantity in endometriotic tissue to the presence of endometriosis-associated infertility.
Time frame: Day 1
Correlation of M1 and M2 macrophages quantity in endometriotic tissue to the presence of endometriosis-associated chronic pelvic pain.
Time frame: Day 1
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Mar 2020.
- Background: PubMed 27306924Kavoussi SK, Lim CS, Skinner BD, Lebovic DI, As-Sanie S. New paradigms in the diagnosis and management of endometriosis. Curr Opin Obstet Gynecol. 2016 Aug;28(4):267-76. doi: 10.1097/GCO.0000000000000288.
- Background: PubMed 24435778Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014 Mar;29(3):400-12. doi: 10.1093/humrep/det457. Epub 2014 Jan 15.
- Background: PubMed 23671540Triolo O, Lagana AS, Sturlese E. Chronic pelvic pain in endometriosis: an overview. J Clin Med Res. 2013 Jun;5(3):153-63. doi: 10.4021/jocmr1288w. Epub 2013 Apr 23.
- Background: PubMed 23738189Buttice S, Lagana AS, Barresi V, Inferrera A, Mucciardi G, Di Benedetto A, D'Amico CE, Magno C. Lumbar Ureteral Stenosis due to Endometriosis: Our Experience and Review of the Literature. Case Rep Urol. 2013;2013:812475. doi: 10.1155/2013/812475. Epub 2013 May 2.
- Background: PubMed 26319653Lagana AS, Condemi I, Retto G, Muscatello MR, Bruno A, Zoccali RA, Triolo O, Cedro C. Analysis of psychopathological comorbidity behind the common symptoms and signs of endometriosis. Eur J Obstet Gynecol Reprod Biol. 2015 Nov;194:30-3. doi: 10.1016/j.ejogrb.2015.08.015. Epub 2015 Aug 15.
- Background: PubMed 7720925Rock JA. The revised American Fertility Society classification of endometriosis: reproducibility of scoring. ZOLADEX Endometriosis Study Group. Fertil Steril. 1995 May;63(5):1108-10. doi: 10.1016/s0015-0282(16)57556-6.
- Background: PubMed 21315335Haas D, Chvatal R, Habelsberger A, Wurm P, Schimetta W, Oppelt P. Comparison of revised American Fertility Society and ENZIAN staging: a critical evaluation of classifications of endometriosis on the basis of our patient population. Fertil Steril. 2011 Apr;95(5):1574-8. doi: 10.1016/j.fertnstert.2011.01.135.
- Background: PubMed 19931076Adamson GD, Pasta DJ. Endometriosis fertility index: the new, validated endometriosis staging system. Fertil Steril. 2010 Oct;94(5):1609-15. doi: 10.1016/j.fertnstert.2009.09.035.
- Background: PubMed 26837776Donnez J, Donnez O, Orellana R, Binda MM, Dolmans MM. Endometriosis and infertility. Panminerva Med. 2016 Jun;58(2):143-50. Epub 2016 Feb 2.
- Background: PubMed 25920525Sofo V, Gotte M, Lagana AS, Salmeri FM, Triolo O, Sturlese E, Retto G, Alfa M, Granese R, Abrao MS. Correlation between dioxin and endometriosis: an epigenetic route to unravel the pathogenesis of the disease. Arch Gynecol Obstet. 2015 Nov;292(5):973-86. doi: 10.1007/s00404-015-3739-5. Epub 2015 Apr 29.
- Background: PubMed 27063075Maniglio P, Ricciardi E, Lagana AS, Triolo O, Caserta D. Epigenetic modifications of primordial reproductive tract: A common etiologic pathway for Mayer-Rokitansky-Kuster-Hauser Syndrome and endometriosis? Med Hypotheses. 2016 May;90:4-5. doi: 10.1016/j.mehy.2016.02.015. Epub 2016 Feb 27. No abstract available.
- Background: PubMed 23843796Lagana AS, Sturlese E, Retto G, Sofo V, Triolo O. Interplay between Misplaced Mullerian-Derived Stem Cells and Peritoneal Immune Dysregulation in the Pathogenesis of Endometriosis. Obstet Gynecol Int. 2013;2013:527041. doi: 10.1155/2013/527041. Epub 2013 Jun 13.
- Individual participant dataSharing planned: Yes
Related trials for Endometriosis
Not yet recruiting
Prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in Women With Endometriosis
SIBO, Endometriosis
Recruiting
Endometriosis Transcriptomic Cell Atlas
Endometriosis, Infertility
Not yet recruiting
Psychotherapy in Patients With Endometriosis: Cognitive Behavioral Therapy Versus Acceptance and Commitment Therapy
Endometriosis, Adenomyosis
Not yet recruitingObservational study
Impact of a Diagnosis or Lack of a Diagnosis of Endometriosis Via a Saliva Test on Pain Catastrophizing, Quality of Life, Symptoms of Anxiety and Depression, and Treatment Adherence
Endometriosis
Not yet recruitingPhase 2
PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
Endometriosis Pelvic, Endometriosis Ovaries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Antonio Simone Laganà, M.D. principal investigator
University of Messina
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Endometriosis, run by University of Messina at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quantification of M1 and M2 macrophages in endometriotic tissue for each stage of endometriosis. (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03136978, which also lists 22 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2020.